# Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis

> **NCT04709575** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 353 (actual)

## Conditions studied

- Allergic Rhinitis
- Conjunctivitis

## Interventions

- **DRUG:** REGN5713
- **DRUG:** REGN5714
- **DRUG:** REGN5715
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04709575
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-14
- **Primary completion:** 2021-08-24
- **Final completion:** 2021-08-24
- **Target enrollment:** 353 (ACTUAL)
- **Last updated:** 2022-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04709575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04709575, "Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04709575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*